Altos Solutions Inc

OncoEMR®

Flatiron Health · Review dated 2026-10-13

Quote-based / not publicly disclosed. The official OncoEMR ONC Certification page says annual subscription fees cover software licenses, customer support, software upgrades and services, and that certified functionality is included at no additional cost unless listed. No official public rate card, trial, promotional price, term, or renewal/proration schedule was found.

Billing model

Quote-based / not publicly disclosed. Official certification disclosure states the commercial structure is a one-time implementation fee plus annual subscription fees; it does not publish dollar amounts, user/patient units, minimums, payment terms, or contract length.

Fees and add-ons

Officially disclosed fee-bearing items (amounts not published): (1) one-time implementation fee for installation; (2) annual subscription; (3) HL7 interfaces may add a one-time implementation fee and annual maintenance subscription—immunization-registry and cancer-registry interfaces are expressly included at no extra cost; (4) data conversions may add a one-time fee depending on converted-data volume; (5) FHIR APIs may incur additional fees per the API documentation; (6) MaxMD electronic referrals, Surescripts general e-prescribing, and DrFirst controlled-substance e-prescribing carry additional one-time and/or annual vendor fees. Interface vendor list is available, but prices/cadence/minimums are not. Current Vendor Network lists independent third parties for ambient AI, telemed/ePRO/triage, pharmacy, prior authorization, financial assistance, RCM and payments; Flatiron expressly says customers contract with those vendors independently, so their rates are not OncoEMR rates. No public implementation/migration/training dollar rates, billing/RCM fees, telehealth fees, payment terms, or minimums found. A dated 2019 Flatiron article says a non-OCM visit-note/custom-report configuration could be provided at no extra cost, but this is promotional/context-specific and not a general current price promise.

Availability and public pricing

Active/currently marketed: Flatiron's current oncology pages describe OncoEMR and related point-of-care offerings; the official certification page lists OncoEMR v2.8 certified December 21, 2022 and a 2025 Real World Test Plan, while the current interface and vendor-network pages remain live. Current capabilities evidenced by official pages include oncology clinical workflows, ordering, billing/practice operations (product-page search result), cloud access, e-prescribing, Direct referrals, EHI export, FHIR/API and HL7 interfaces. No evidence found that OncoEMR has been discontinued. The 2025 Paradigm clinical-research transaction affects clinical-research support/partnership, not the EHR's active status. Product page fetch returned an unrelated case-study body despite its OncoEMR title, so feature claims were cross-checked against certification, interfaces, vendor-network and current oncology pages.

Qualifications

All findings are limited to official Flatiron pages/PDFs opened and read; no third-party price aggregators or snippets used. The official certification page is the strongest pricing source but gives only fee categories, not amounts. Public materials do not disclose trial availability, term, minimum commitment, payment schedule, implementation/migration/training rates, or exact FHIR pricing. The value-based-care PDF and OCF article contain older/promotional or program-specific language and should not be treated as current universal inclusions. Third-party Vendor Network services (including telemed, RCM, payments and pharmacy) are explicitly independent contracts and may be priced separately.